National Health Investors, Inc. (NHI)
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
$70.88-1.43%
Close 2026-09-04 · 1-day change
NYSEReal EstateReit - Healthcare FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · NHI
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $71 NHI trades at 13× p/ffo, in line with its 13× p/ffo peer median, and our $72 fair value agrees. We hold it with medium confidence: our number sits below the analyst range. Analysts target $78–$81. Note: our $72 fair value sits below the entire analyst range ($78–$81). Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $80.00 | — | — | Analyst | high |
| dcf fcff | 12M | $246.07 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $66.98 | — | — | TTM | high |
| graham number | 12M | $53.24 | — | — | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$78.00 – $81.00 (median $80.00) · 5 analysts · as of 2026-09-02
Only weak execution quality — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $73.83 |
| 15.6 |
| 4.74 |
| TTM |
| high |
| Peer P/FFO | 12M | $70.58 | 13.2 | 5.35 | TTM | high |
| Peer P/S | 12M | $34.12 | 3.8 | 8.91 | TTM | high |
| residual income | 12M | $37.41 | — | — | TTM | high |
| Own P/E history | 12M | $84.92 | 21.9 | 3.87 | TTM | high |
| triangulated | 12M | $51.81 | 13.2 | 3.93 | Triangulated | high |
| Peer P/FCF | 3Y | $112.28 | 15.6 | 7.21 | Hist. CAGR(prov.) | medium |
| Peer P/FFO | 3Y | $101.26 | 13.2 | 7.67 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $12.67 | 3.8 | 3.31 | Analyst | medium |
| Own P/E history | 3Y | $58.66 | 21.9 | 2.67 | Analyst | medium |
| Peer P/FCF | 5Y | $148.50 | 15.6 | 9.54 | Hist. CAGR(prov.) | medium |
| Peer P/FFO | 5Y | $128.80 | 13.2 | 9.76 | Hist. CAGR(prov.) | medium |
| Own P/E history | 5Y | $30.30 | 21.9 | 1.38 | Analyst | medium |